Core Viewpoint - Salarius Pharmaceuticals, Inc. will implement a 1-for-8 reverse stock split to comply with Nasdaq's minimum bid price requirement of $1.00, effective June 14, 2024 [1][7]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 4.7 million to about 0.6 million [8]. - The reverse split was approved by stockholders on May 9, 2024, and the specific ratio was determined by the Board of Directors [1][8]. - All outstanding options and warrants will be adjusted accordingly, and stockholders will receive cash for any fractional shares based on the closing price on June 14, 2024 [8]. Group 2: Company Background - Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing cancer therapies, including seclidemstat for pediatric cancers and SP-3164 for non-Hodgkin's lymphoma [10]. - The company has received financial support from the National Pediatric Cancer Foundation and a Product Development Award from the Cancer Prevention and Research Institute of Texas [10].
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split